CSTL Q2 2025 Earnings — Castle Biosciences, Inc. Revenue & Financial Results | Market Cap Arena

CSTLCastle Biosciences, Inc.

$805M

Q2 2025 Earnings

Healthcare Medical - Diagnostics & Research

Income Statement

Revenue

$86M-0.9% YoY

Gross Profit

$69M79.5% margin

Operating Income

-$4M-4.9% margin

Net Income

$5M5.2% margin

EPS (Diluted)

$0.15

QoQ Revenue Growth

-2.0%

Cash Flow

Operating Cash Flow

$21M

Free Cash Flow

$12M

Stock-Based Comp.

$11M

Balance Sheet

Total Assets

$545M

Total Liabilities

$89M

Stockholders' Equity

$455M

Cash & Equivalents

$82M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$86M	$87M	-0.9%
Gross Profit	$69M	$72M	-5.4%
Operating Income	-$4M	$5M	-184.8%
Net Income	$5M	$9M	-49.3%

Revenue Segments

Dermatologic

$56M100%